Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis
RMAT designation potentially streamlines the path to market approval by allowing frequent interactions with FDA and routes to FDA Accelerated Approval and Priority Review
Enrollment in NEXICART-2 study accelerating; next update planned for H1 2025
LOS ANGELES,CA, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) ('ImmixBio', 'Company', 'We' or 'Us', 'IMMX'), a clinical-stage biopharmaceutical company developing cell therapies for AL amyloidosis and select immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted RMAT designation to sterically-optimized CAR-T NXC-201 for the treatment of relapsed/refractory AL amyloidosis. As of June 2024 public information, FDA approved less than half of RMAT applications submitted to the agency during the last eight years. FDA RMAT designation requires that a drug is an advanced regenerative medicine, targets a serious condition, with the potential to treat, modify, reverse, or cure, and preliminary clinical evidence has indicated that the drug has the potential to address these unmet medical needs.
'Receipt of FDA RMAT designation underscores the strength of our NXC-201 data and the potential for NXC-201 to provide a new treatment option for patients with relapsed/refractory AL amyloidosis, where no drugs are FDA approved today,' said Ilya Rachman, MD, PhD, Chief Executive Officer of Immix Biopharma. Gabriel Morris, Chief Financial Officer of Immix Biopharma, added, 'We are also pleased to report that the pace of enrollment in NEXICART-2 has accelerated, following successful completion of the safety run-in segment. We look forward to sharing further information on our progress, including an update on NEXICART-2, in the first half of 2025.'
The RMAT designation is intended to accelerate the development and review of promising investigational products, including cell therapies. To qualify, a product must be designed to treat, modify, reverse, or cure a serious or life-threatening disease, with preliminary clinical evidence suggesting it can address unmet medical needs. The RMAT designation offers several key advantages, including early and frequent interactions with the FDA to discuss potential surrogate or intermediate endpoints, as well as strategies to meet post-approval requirements, potentially streamlining the path to market approval.
NXC-201 is the only CAR-T therapy currently in development in AL Amyloidosis, mentioned in a review article entitled 'Systemic Light Chain Amyloidosis' published in June, 2024 New England Journal of Medicine.
About NXC-201NXC-201 is a sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy. Initial data from Phase 1b/2 ex-U.S. study NEXICART-1 has demonstrated high complete response rates and no neurotoxicity of any kind in relapsed/refractory AL Amyloidosis.
NXC-201 is being studied in a comprehensive U.S. clinical development program for the treatment of patients with relapsed/refractory AL amyloidosis, with the potential to expand into select immune-mediated diseases. The NXC-201 NEXICART-2 (NCT06097832) U.S. clinical trial builds on a robust clinical dataset. NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the FDA, and Orphan Drug Designation (ODD) by the US FDA and in the EU by the EMA.
About NEXICART-2NEXICART-2 (NCT06097832) is an open-label, single-arm, multi-site U.S. Phase 1b/2 dose expansion clinical trial of CAR-T NXC-201 in relapsed/refractory AL Amyloidosis. NEXICART-2 is expected to enroll 40 patients with preserved heart function (excluding patients with pre-existing heart failure) who have not been exposed to prior BCMA-targeted therapy. The study is designed with a standard 6 patient safety-run in to evaluate two doses (three patients each at 150 million CAR+T cells and 450 million CAR+T cells) (both dose levels were evaluated in the NEXICART-1 study and have produced complete responses in relapsed/refractory AL Amyloidosis patients). The study aims to evaluate the safety and efficacy of NXC-201. Primary endpoints are complete response rate and overall response rate, according to consensus recommendations (Palladini et al. 2012).
About AL AmyloidosisAL amyloidosis is caused by abnormal plasma cells in the bone marrow, which produce misfolded amyloid proteins that build-up in the heart, kidney, liver, and other organs. This build-up causes progressive and widespread damage to multiple organs, including heart failure, and leads to high mortality rates.
The U.S. observed prevalence of relapsed/refractory AL Amyloidosis is estimated to be growing at 12% per year according to Staron, et al Blood Cancer Journal, to approximately 33,277 patients in 2024.
The Amyloidosis market was $3.6 billion in 2017, and is expected to reach $6 billion in 2025, according to Grand View Research.
About Immix Biopharma, Inc.Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and select immune-mediated diseases. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201. NXC-201 is being evaluated in the U.S. Phase 1b/2 trial NEXICART-2 (NCT06097832) as well as the ex-U.S. study NEXICART-1 (NCT04720313). NXC-201 has demonstrated no neurotoxicity of any kind in AL Amyloidosis, supporting expansion into select immune-mediated diseases. NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA. Learn more at www.immixbio.com and www.BeProactiveInAL.com.
Forward Looking StatementsThis press release contains forward-looking statements regarding Immix Biopharma, Inc., its results of operations, prospects, future business plans and operations and the matters discussed above, including, but not limited to, the potential benefits of our product candidate CAR-T NXC-201 and the timing and results related clinical trials. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements also include, but are not limited to, our plans, objectives, expectations and intentions and other statements that contain words such as 'expects', 'contemplates', 'anticipates', 'plans', 'intends', 'believes', 'estimates', 'potential', and variations of such words or similar expressions that convey the uncertainty of future events or outcomes, or that do not relate to historical matters. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the further data from the ongoing Phase 1b/2 clinical trials for CAR-T NXC-201 will not be favorably consistent with the data readouts to date, (ii) the risk that the Company may not be able to continue the NEXICART-2 multi-site U.S. Phase 1b/2 clinical trial; (iii) the risk that the Company may not be able to advance to registration-enabling studies for CAR-T NXC-201 or other product candidates, (iv) that success in early phases of pre-clinical and clinicals trials do not ensure later clinical trials will be successful; (v) that no drug product developed by the Company has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (vi) the risk that the Company may not be able to obtain additional working capital with which to continue the clinical trials for CAR-T NXC-201, or advance to the initiation of registration-enabling studies, for such product candidates as and when needed and (vii) those other risks disclosed in the section 'Risk Factors' included in the Company's Annual Report on Form 10-K filed with the SEC on March 29, 2024 and other periodic reports subsequently filed with the Securities and Exchange Commission. These reports are available at www.sec.gov. Immix Biopharma cautions that the foregoing list of important factors is not complete. Immix Biopharma cautions readers not to place undue reliance on any forward-looking statements. Immix Biopharma does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
ContactsMike MoyerLifeSci Advisorsmmoyer@lifesciadvisors.com
Company Contactirteam@immixbio.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Collagen Supplement Trends in 2025: Why Pilly Labs Collagen Gummies Are Leading the Natural Glow-Up Movement
As consumer demand for clean beauty and functional supplements rises in 2025, marine collagen gummies like Pilly Labs are emerging as a preferred daily solution for supporting skin texture, joint mobility, and hair strength — all without powders, pills, or synthetic additives. New York, Aug. 02, 2025 (GLOBE NEWSWIRE) -- This press release is for informational purposes only. The information contained herein does not constitute medical advice, diagnosis, or treatment and has not been evaluated by the Food and Drug Administration (FDA). Collagen Supplement is not intended to diagnose, treat, cure, or prevent any disease. Always consult your physician or qualified healthcare provider before beginning any new supplement, routine, or health program. Some links in this release may be promotional in nature and may lead to third-party websites. The publisher or author may receive compensation through affiliate commissions if a purchase is made through these links. This compensation does not affect the price you pay and helps support continued research and content publication. Results described or implied may not be typical and should not be interpreted as guarantees. Statements made about ingredients or outcomes reflect public discussion and historical usage only, and are not endorsed by medical professionals or regulatory agencies. Always do your own research and make informed decisions. Collagen Supplement Trends in 2025: Why Pilly Labs Collagen Gummies Are Leading the Natural Glow-Up Movement As more people turn to natural solutions for skin, joint, and hair support, collagen supplements have become a top trend in wellness for 2025. Pilly Labs Collagen Gummies, a marine-based collagen supplement enhanced with Vitamin C, Biotin, and Zinc, are rapidly gaining attention for their clean-label design and long-term beauty support. With consumer interest in inside-out health and sustainable self-care at an all-time high, this functional formula offers a delicious and effective way to build a glow-up routine that fits today's wellness demands. From skincare influencers to wellness podcasts and TikTok self-care trends, the spotlight on collagen supplementation has never been brighter. As consumers seek more natural, effective ways to support their skin's elasticity, joint mobility, and hair strength, collagen has emerged as a foundational nutrient in the 2025 health and beauty landscape. But not all collagen products are created equal — and that's where Pilly Labs Collagen Gummies are beginning to stand out. This new wave of clean, marine-sourced collagen supplements is redefining how modern consumers approach beauty from within. Ready to support glowing skin, strong hair, and resilient joints from the inside out?Explore the Full Pilly Labs Collagen Supplement Formula Today Why Interest in Collagen Supplement Is Surging in 2025 Collagen supplements have exploded across TikTok, Google search, and wellness podcasts in 2025 — driven by rising demand for skin-plumping nutrients, joint resilience, and visible glow-up routines that feel both natural and effective. Monthly search volume for 'collagen supplement' has surged past 400,000 in the U.S. alone, fueled by Gen Z and Millennial audiences looking for non-invasive ways to support aging, mobility, and beauty from within. On TikTok, creators are documenting 30-day collagen challenges, while Reddit users are compiling ingredient spreadsheets comparing marine peptides, hydrolyzed formulas, and absorption-enhancing stacks. The term 'collagen routine' now appears in skincare, gut health, and even fitness hashtags, revealing how mainstream this once-niche supplement category has become. What makes 2025 different? Consumers are no longer just buying products based on claims — they're researching clinical studies, comparing formulations, and tracking their personal results over 3-, 6-, and 12-month use periods. That's why long-term, habit-forming delivery formats like collagen gummies are growing rapidly compared to powders or pills. The shift is also linked to what trend analysts call 'beauty rationalism' — the belief that if your body can rebuild its own structures from the inside, you'll age better naturally. And in that framework, collagen isn't hype — it's a foundational building block. Collagen Supplement's Ingredient-First Response to These Trends As public demand for long-term wellness routines grows, a new generation of supplement users is prioritizing clean sourcing, formulation transparency, and ingredient synergy. Pilly Labs Collagen Gummies meet that demand head-on — not through hype or aggressive marketing, but through an ingredient-first design philosophy that aligns with the modern consumer's standards for internal beauty support. At the core of the formula is hydrolyzed marine collagen — a highly bioavailable peptide source derived from wild-caught fish like tilapia and cod. Marine collagen is frequently explored in collagen research circles for its smaller molecular weight, which may aid digestion and uptake compared to bovine or porcine sources. Pilly Labs chose this collagen type specifically for its solubility, sustainability, and wide acceptance in clean-label beauty stacks. But collagen alone isn't enough. That's why the formula incorporates supportive nutrients like Vitamin C (ascorbic acid), Biotin (D-Biotin), Zinc (from citrate), and Vitamin E — each frequently discussed for their role in structural skin protein formation, hair integrity, and cellular repair. These additions position the formula within the broader trend of 'co-factor supported supplementation,' a movement where each ingredient amplifies the others through intelligent synergy. The delivery format itself also plays a key role. Unlike messy powders or oversized capsules, Pilly Labs uses a fruit-flavored gummy that's easy to take daily — a decision made to improve user compliance over the full 90-day to 6-month collagen renewal cycle. This convenience-forward format is backed by a growing body of user behavior data showing that daily habit consistency is a major predictor of visible results. Finally, the formula avoids additives that many wellness-savvy buyers now actively exclude. Pilly Labs Collagen Gummies are gluten-free, non-GMO, antibiotic-free, and made without artificial sweeteners or dyes. Even the coloring is derived from natural purple carrot concentrate — another nod to the brand's clean beauty alignment. Curious how marine collagen, Biotin, and Vitamin C work together for long-term beauty support?See the Full Breakdown of Pilly Labs Collagen Gummies Here Ingredient Spotlight – What's Inside the Formula Understanding what's inside a collagen supplement is just as important as knowing why to take one. Pilly Labs Collagen Gummies were formulated with a clear goal: to reflect the most talked-about, synergistic nutrients in the world of beauty-from-within, without relying on synthetic additives or filler ingredients. The core of the formula is hydrolyzed collagen peptides — marine-derived proteins that are frequently associated with skin elasticity, hair structure, and joint cushioning in wellness routines. Unlike raw collagen, hydrolyzed peptides are smaller in molecular weight, which is why they are often explored for improved absorption in digestive and skin health regimens. To enhance this collagen foundation, Pilly Labs includes Vitamin C (Ascorbic Acid) — a well-known antioxidant that is commonly referenced in research on collagen synthesis. Vitamin C helps support the body's natural process of turning collagen peptides into usable structural proteins, making it one of the most essential co-nutrients in any beauty formula. Also featured is Biotin (D-Biotin) — a B-complex vitamin frequently discussed in hair, skin, and nail support communities. Biotin plays a role in keratin production and is a popular inclusion in wellness stacks focused on hair thickness and nail strength. The formula also provides Zinc (from Zinc Citrate) — a trace mineral that has been explored for its relevance to tissue repair and barrier function. In holistic supplementation circles, zinc is often combined with collagen to support overall skin integrity. Vitamin E (as DL-Alpha-Tocopheryl Acetate) rounds out the antioxidant support, helping protect cells from oxidative stress — a common factor in visible aging and structural protein breakdown. Other supportive elements include Glycine (a primary amino acid in collagen itself), natural fruit-based sweeteners like purple carrot juice concentrate, and a plant-based gummy matrix using pectin and coconut oil instead of gelatin or synthetic binders. By combining these elements into a single, clean-label delivery system, Pilly Labs positions its collagen supplement at the intersection of science-backed structure and modern ingredient transparency — key factors in today's high-trust wellness economy. What Reddit, Podcasts & TikTok Creators Are Saying In 2025, social platforms like TikTok, Reddit, and Spotify-hosted wellness podcasts have become central hubs for everyday users to explore supplements, routines, and health experiments. Among them, collagen supplementation — especially in gummy form — continues to trend as one of the most discussed daily rituals in beauty and longevity communities. On TikTok, creators are showcasing their 30-, 60-, and 90-day glow-up challenges using collagen, often in 'before and after' style videos documenting changes in skin texture, hair bounce, and morning mobility. Hashtags like #collagengummies, #marinecollagen, and #skinglowup2025 are attracting millions of views, with users comparing brands based on ingredient transparency and how easy the format is to stick with. Reddit threads across r/Supplements, r/SkincareAddiction, and r/Healthygamergg have seen growing curiosity around how marine collagen differs from bovine-based formulas, whether gummies are as effective as powders, and what real users are experiencing after three months of daily use. The tone is rarely prescriptive — instead, it's marked by personal testing, ingredient breakdowns, and crowdsourced feedback loops. Meanwhile, in the podcast space, wellness influencers and holistic nutritionists are dedicating full episodes to 'collagen stacking,' where listeners explore how nutrients like Biotin and Vitamin C work in synergy with peptides. Marine collagen often gets attention for its sustainability angle and smaller molecular structure, while gummies continue to be praised for compliance and taste. Across all platforms, the most common thread is not hype — it's habit. Content creators consistently focus on what's easy to maintain over months, not just what works for a few days. That's part of why products like Pilly Labs Collagen Gummies — with their clean label, taste-first design, and non-disruptive format — fit into the routines people are already building around skincare, nutrition, and long-term vitality. Looking for a collagen supplement that's clean, effective, and easy to take every day?Discover Why Pilly Labs Collagen Gummies Are Leading in 2025 Who Might Be Drawn to This Type of Supplementation in 2025 The rise of collagen supplementation in 2025 is being driven not by any single demographic, but by a wide spectrum of lifestyle mindsets — each with its own reasons for embracing daily nutrient routines. Pilly Labs Collagen Gummies are not positioned for one type of consumer, but rather align with the habits, values, and routines of individuals seeking long-term, structural wellness support. Biohackers and longevity-focused early adopters are often drawn to marine collagen because of its inclusion in 'stacked' wellness protocols. These consumers are constantly researching ingredients that support cellular health, structural proteins, and graceful aging — and they tend to prefer formats that are easy to integrate into repeatable daily cycles. Skincare-first consumers — particularly those building out multi-step regimens — are turning to internal supplements like collagen to complement their topical routines. For these users, the appeal lies in enhancing skin texture, bounce, and hydration by supporting deeper structural layers over time. Consistency is everything, which is why gummy delivery is favored for ease and habit formation. Wellness lifestyle seekers, often in their 30s to 50s, are focused on maintaining energy, appearance, and movement without introducing drastic changes to their routines. These individuals tend to favor non-invasive solutions — ones that feel like a natural part of their morning or evening ritual, not a medical intervention. Active adults and fitness-conscious individuals are another growing segment. These users explore collagen supplementation as part of their joint-support strategy, especially if they're already following clean eating and workout protocols that emphasize recovery and longevity. Lastly, first-time supplement users looking for a gentle introduction to functional beauty routines often choose gummies as a low-friction entry point. The flavor, format, and simplified dosing make collagen supplementation feel more like self-care than medicine — which increases the likelihood of long-term habit adoption. In each case, it's not just about what a supplement does — it's about how easily it fits into a lifestyle built around sustainability, wellness, and proactive aging. Spiritual Optimization & Collagen Curiosity – 2025 Market Reflections The wellness industry in 2025 is evolving beyond traditional health categories. As consumers become more self-aware and future-oriented, a new area of interest is emerging — often described as 'spiritual optimization' or 'conscious wellness.' While still rooted in physical health, this movement explores how daily rituals contribute to emotional clarity, balance, and long-term vitality. Within this context, collagen supplementation has quietly entered the conversation — not as a spiritual tool, but as part of a broader desire for alignment between internal health and external presence. Individuals seeking routines that support calm, glow, and groundedness often turn to products that feel intentional, clean, and self-honoring. Pilly Labs Collagen Gummies are not marketed as spiritual products, but their design reflects many of the values embraced by this consumer segment: natural sourcing, simplicity, and ease of integration into meaningful rituals. Whether it's part of a morning meditation, a skincare wind-down, or a 6AM cold plunge routine, the daily gummy becomes a tactile anchor for self-investment — a micro-commitment to long-term care. This rising interest in 'functional clarity' — where beauty, mood, and longevity intersect — is fueling growth in clean-label, habit-focused supplements that avoid synthetic compounds or hard-sell marketing. Collagen is increasingly seen not just as a cosmetic support, but as part of a lifestyle rooted in maintenance, not repair. Importantly, this reflection is not tied to any belief system or metaphysical claim. Instead, it mirrors a cultural shift toward ritualizing wellness, where collagen fits naturally alongside journaling, hydration tracking, and screen-time reduction. Consumers want support that's subtle, structural, and sustainable — not flashy or overstated. Learn More About Pilly Labs' Marine Collagen Approach The Public Debate Around Collagen – Signals, Skepticism, and Saturation As collagen continues to gain traction in the wellness and beauty space, so too has public discourse evolved. In 2025, the conversation around collagen supplementation isn't just about benefits — it's also about evidence, overexposure, and what counts as meaningful results. Pilly Labs Collagen Gummies enter this landscape at a moment when consumers are asking better questions and expecting more transparency. Positive Signals:Some view the widespread adoption of collagen as a sign that consumers are becoming more proactive about aging, structure, and long-term wellness. This group sees collagen not as a magic bullet, but as a consistent, foundational element of functional health — the same way protein or hydration has become essential to daily maintenance. Supporters often highlight the importance of delivery format, ingredient sourcing, and duration of use when evaluating results, with many leaning toward marine collagen due to its bioavailability and sustainability profile. Skeptical Voices:Others raise valid concerns about whether collagen supplementation lives up to its growing list of perceived benefits. Common points of contention include whether externally sourced collagen can significantly impact internal regeneration, whether brands are overstating cosmetic outcomes, or whether differences between marine, bovine, and porcine types actually matter. This segment of the conversation often calls for more third-party verification, longer clinical timelines, and consumer protections around exaggerated marketing. Neutral Observers:A third perspective — increasingly common among health-savvy consumers — is one of measured experimentation. These users don't expect overnight transformation. Instead, they test products for 3 to 6 months, track skin hydration, joint comfort, and hair resilience, and make purchasing decisions based on real-world fit. They are less influenced by influencer marketing and more aligned with community discussion, reviews, and ingredient transparency. For this group, collagen is one small part of a broader health optimization plan. In a saturated market, credibility comes from clarity — and brands that acknowledge all sides of the debate while maintaining honest, educational messaging tend to earn the most long-term trust. About Pilly Labs Pilly Labs is part of a new generation of wellness companies that prioritize clean beauty, transparency, and long-term health habits over hype. Founded with the belief that better routines begin with better ingredients, the company creates products that support structural wellness — without cutting corners on sourcing, science, or sustainability. The brand's mission is simple: to make foundational health support more accessible, enjoyable, and effective for people seeking internal balance and external confidence. With an ingredient-first philosophy, Pilly Labs formulates each supplement to reflect current research, real consumer needs, and modern preferences for ease, taste, and trust. Pilly Labs Collagen Gummies are a direct result of that philosophy. Each gummy is formulated with hydrolyzed marine collagen peptides, combined with nutrient cofactors like Vitamin C, Biotin, Zinc, and Vitamin E — all frequently discussed in wellness communities for their potential to support skin structure, hair health, and mobility from within. But it's not just about what's inside. Pilly Labs pays close attention to what's excluded, too. The gummies are free from gluten, artificial sweeteners, antibiotics, and synthetic dyes. Even the color and flavor come from natural sources like purple carrot juice concentrate and citrus oils — a nod to the company's broader clean beauty commitment. Rather than chasing fads or flashy claims, Pilly Labs focuses on consistency, education, and sustainability. The goal isn't to promise instant results — it's to help people build simple, effective routines they can stick with for months or years to come. By making high-quality collagen accessible through a convenient gummy format, the company empowers users to take ownership of their beauty and wellness journey with confidence. Tired of powders and pills that disrupt your routine or taste artificial?Try the Collagen Gummy That's Designed for Simplicity and Results Contact Pilly Labs Email Support: info@ Website: Final Disclaimer This press release is for informational purposes only. The information contained herein does not constitute medical advice, diagnosis, or treatment and has not been evaluated by the Food and Drug Administration (FDA). Collagen Supplement is not intended to diagnose, treat, cure, or prevent any disease. Always consult your physician or qualified healthcare provider before beginning any new supplement, routine, or health program. Some links in this release may be promotional in nature and may lead to third-party websites. The publisher or author may receive compensation through affiliate commissions if a purchase is made through these links. This compensation does not affect the price you pay and helps support continued research and content publication. Results described or implied may not be typical and should not be interpreted as guarantees. Statements made about ingredients or outcomes reflect public discussion and historical usage only, and are not endorsed by medical professionals or regulatory agencies. Always do your own research and make informed decisions. CONTACT: Email Support: info@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
RCKT Deadline: Rosen Law Firm Urges Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action lawsuit on behalf of purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between September 17, 2024 and May 26, 2025. Rocket Pharmaceuticals is a fully integrated, late-stage biotechnology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) Misled Investors Regarding its Business Operations. According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) RP-A501 was less effective than defendants had led investors to believe; (2) to increase its effectiveness, Rocket Pharmaceuticals amended RP-A501's clinical trial protocol by introducing a novel immunomodulatory agent; (3) the foregoing increased the risk that patients would suffer from a Serious Adverse Event ('SAE'); (4) accordingly, RP-A501's safety, as well as its clinical, regulatory, and commercial prospects, were overstated; and (5) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against Rocket Pharmaceuticals, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by August 11, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.
Yahoo
2 hours ago
- Yahoo
The Ocean Floor Could Power EVs. Will This Company Reap the Rewards?
Key Points The Metals Company is developing tech to harvest metal-rich nodules from the ocean floor. The company has no revenue and is still awaiting regulatory approval to begin mining. A recent U.S. permit application could offer The Metals Company an alternative path forward. 10 stocks we like better than TMC The Metals Company › Imagine diving into the Pacific Ocean's depths, not to see coral reefs or look for sunken pirate treasure, but to gather metal-dense rocks containing materials that can power the electric vehicle (EV) revolution. That, in a nutshell, is the bold vision of The Metals Company (NASDAQ: TMC), a Vancouver-based company aiming to vacuum polymetallic nodules from the seafloor. With a stock that had soared 430% in 2025 as of market close July 31, TMC has caught the eyes of investors betting on a future of green energy. But with no revenue, mounting losses, and a sea of risks, is this materials stock worth diving into? Let's explore. What does The Metals Company do? TMC isn't your typical mining stock. The company's core mission is to harvest polymetallic nodules from a remote stretch of Pacific Ocean known as the Clarion Clipperton Zone (CCZ). These lumpy, fist-sized seafloor stones are loaded with nickel, copper, cobalt, and manganese, all essential ingredients in everything from electric vehicle batteries to solar panels. On land, these rare earth metals are mined and processed in carbon-heavy ways, which ironically undercut the clean-tech future many are destined to be part of. TMC wants to flip the script. Instead of digging holes in the earth, it wants to scoop metal-rich nodules from the seabed and refine them into battery-grade materials, possibly with a lighter environmental footprint. The potential for TMC's mining operations is huge. As Henry Sanderson points out in his book Volt Rush: The Winners and Losers in the Race to Go Green, the deep sea holds more nickel, cobalt, and possibly other rare earth metals than all the world's land-based reserves combined. The CCZ alone is believed to contain some 21 billion metric tons of nodules -- enough raw material to not only shake China's grip on battery metals but supercharge the EV revolution for decades, if the materials can be gathered and refined. A big vision, but zero revenue But let's not sugarcoat it: TMC is nowhere near harvesting nodules at a commercial scale. The company reported zero revenue in the first quarter of 2025, paired with a net loss of about $20.6 million. That loss widened from $16.1 million in the quarter before. It turns out that building an underwater mining infrastructure from scratch isn't going to be cheap. Or quick. As of writing, TMC still doesn't have the green light to mine commercially in the CCZ. Although it holds exploration rights across two massive patches there, it doesn't yet have permission to start harvesting the goods. That authority rests with the International Seabed Authority (ISA), a United Nations-backed body that still hasn't finalized the regulatory playbook that companies like TMC need to operate. But there's a plot twist with the ISA: The U.S. never ratified the treaty that made the agency. While 169 nations and the European Union formally recognize the agency's authority, the U.S. isn't one of them. True, it does acknowledge parts of the treaty as international law, but technically, it's not bound by the ISA's rulebook. This means that if national interest comes into play -- say, securing domestic access to critical minerals -- the U.S. could try to go its own way. That would give companies like TMC a potential fast track to start operating in the CCZ. This is exactly the door that TMC is trying to walk through. In April 2025, the company filed a permit application under a decades-old U.S. law just days after President Donald Trump signed a U.S. executive order renewing interest in offshore critical minerals. If TMC's application is approved, it could mean mining under American jurisdiction in waters considered off-limits to the rest of the world. It's a long shot, legally speaking, and could breach international norms, but it would be a major breakthrough for a company with no revenue. A long-term wager with caveats TMC is what I'd call a moonshot (or, maybe a deep-sea Hail Mary) -- it's a big idea with big risks and potentially big payoffs. If the permits come through and the tech scales, today's price could look like a bargain. After all, a $2.65 billion market cap could look small compared to the multitrillion-dollar demand for battery metals that's expected over the next few decades. If TMC becomes even a minor supplier in that chain, its top-line growth could dwarf what investors are paying today. But if the ISA blocks its permit, or if U.S. jurisdiction doesn't hold up to legal scrutiny, or if other things turn out in ways not the best for the company, TMC could keep burning cash with no clear path to revenue. That's a lot of "ifs." Clearly, this isn't a stock for the risk-averse. For aggressive investors with long-term horizons, a small stake might make sense as part of a diversified portfolio. But I would wait for tangible progress, like a confirmed mining license, before scaling up exposure. Should you buy stock in TMC The Metals Company right now? Before you buy stock in TMC The Metals Company, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and TMC The Metals Company wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Steven Porrello has positions in TMC The Metals Company. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The Ocean Floor Could Power EVs. Will This Company Reap the Rewards? was originally published by The Motley Fool Sign in to access your portfolio
